865 results on '"Volin, L"'
Search Results
2. Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation
3. Epstein-Barr Viral Load and Disease Prediction in a Large Cohort of Allogeneic Stem Cell Transplant Recipients
4. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT
5. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
6. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
7. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
8. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
9. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
10. Management and outcome of myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia relapsing after allogeneic stem cell transplantation: a retrospective analysis on 888 patients by the MDS Subcommittee of the EBMT Chronic Leukaemia Working Party
11. Allogeneic stem cell transplantation for acute myeloid leukemia with normal cytogenetics (CN-AML): outcome, risk factors and role of molecular subgroups in 1006 patients - a report from the Acute Leukemia Working Party of EBMT [Abstract]
12. Factors determining the kinetics of disease relapse after allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukaemia (AML): a survey from the Acute Leukaemia Working Party of the EBMT [Abstract]
13. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
14. What is the outcome in patients with acute leukaemia who survive severe acute graft‐versus‐host disease?
15. More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party
16. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
17. Diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome of the liver: problems of interpretation
18. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)
19. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT
20. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
21. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT
22. Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
23. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
24. Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
25. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation
26. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT
27. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation
28. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia
29. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings
30. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT
31. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning
32. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
33. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium
34. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
35. Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD
36. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT
37. Invasive Aspergillus infections in allo-SCT recipients: environmental sampling, nasal and oral colonization and galactomannan testing
38. Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT
39. IMPACT OF THE HEMATOPOIETIC STEM CELL SOURCE IN ALLOGENEIC HSCT IN PAEDIATRIC ALL: A RETROSPECTIVE STUDY ON BEHALF OF THE EBMT PAEDIATRIC DISEASES WORKING PARTY: PH-P285
40. SIGNIFICANCE OF ACHIEVING SECOND CHRONIC PHASE PRIOR TO ALLOGENEIC STEM CELL TRANSPLANT FOLLOWING TYROSINE KINASE INHIBITOR THERAPY: A RETROSPECTIVE STUDY FROM THE CHRONIC MALIGNANCY WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION: PH-P099
41. REDUCED INTENSITY ALLOGENEIC SCT ACHIEVES LONG TERM DISEASE CONTROL IN PATIENTS WITH FOLLICULAR LYMPHOMA RELAPSING AFTER A PRIOR AUTOLOGOUS SCT AND MAY OVERCOME THE ADVERSE IMPACT OF EARLY RELAPSE POST AUTOSCT. AN EBMT LYMPHOMA WORKING PARTY ANALYSIS: PH-O108
42. THE REVISED IPSS (IPSS-R) AT TRANSPLANT PREDICTS OVERALL AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MDS/SAML: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY: WP-O014
43. CONDITIONING INTENSITY IN MIDDLE AGED PATIENTS WITH AML IN CR1. NO ADVANTAGE FOR MYELOABLATIVE REGIMENS IRRESPECTIVE OF THE RISK GROUP. AN OBSERVATIONAL ANALYSIS BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT: PH-O148
44. REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA: A COMPARISON OF TANDEM AUTO-ALLOGRAFT TO EARLY REDUCED INTENSITY ALLOGRAFT AS UPFRONT TRANSPLANT: AN EBMT ANALYSIS ON BEHALF OF THE PLASMA CELL DISORDERS: PH-O144
45. ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS (CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT: PH-O127
46. PROGNOSTIC SIGNIFICANCE OF EBMT SCORE FOR CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE ERA OF TYROSINE KINASE INHIBITOR THERAPY: A RETROSPECTIVE STUDY FROM THE CHRONIC MALIGNANCY WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT): PH-O064
47. IMPACT OF CYTOGENETIC USING THE IPSS REVISED CYTOGENETIC CLASSIFICATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS OR AML EVOLVING FROM MDS: A RETROSPECTIVE MULTICENTER STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT: PH-O012
48. ALLOGENEIC AND AUTOLOGOUS HSCT FOR ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. AN ANALYSIS FROM ACUTE LEUKEMIA WORKING PARTY OF THE EBMT: PH-O008
49. TREOSULFAN BASED CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOGENOUS LEUKEMIA (AML): A RETROSPECTIVE ANALYSIS FROM THE ALWP OF THE EBMT: PH-O010
50. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.